Systematic review: Antibodies and anti-TNF-α levels in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 9, 2012, Pages 971-986

  Chaparro, M ^a   Guerra, I ^b   Munoz Linares P ^a   Gisbert, J P ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN G1; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBODY BLOOD LEVEL; ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN BINDING; APOPTOSIS; ARTHRALGIA; CHRONIC INFLAMMATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DOSAGE SCHEDULE COMPARISON; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DYSPNEA; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FACE EDEMA; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; MAINTENANCE THERAPY; MYALGIA; NAUSEA; NONHUMAN; PATIENT CARE; PERIPHERAL EDEMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; PRURITUS; PSORIATIC ARTHRITIS; RADIOIMMUNOASSAY; REVIEW; RHEUMATOID ARTHRITIS; SORE THROAT; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; HUMANS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875725735     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05057.x     Document Type: Review

References (59)

1. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-57.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
4. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
5. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387-98.
6. Decker T, Lohmann-Matthes ML, Gifford GE. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 1987; 138: 957-62.
7. Parry SL, Sebbag M, Feldmann M, Brennan FM. Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNFalpha. J Immunol 1997; 158: 3673-81.
8. Caron G, Delneste Y, Aubry JP, et al. Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha-dependent cytotoxic activity. Eur J Immunol 1999; 29: 3588-95.
9. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factoralpha from cells. Nature 1997; 385: 729-33.
10. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17: 331-67.
11. Chowers Y, Sturm A, Sans M, et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis 2010; 4: 367-76.
12. Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 1998; 161: 2636-41.
13. Lee TW, Fedorak RN. Tumor necrosis factor-alpha monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am 2010; 39: 543-57.
14. Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35: 757-73.
15. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-75.
16. Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 2008; 22: 331-7.
17. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010; 49: 1215-28.
18. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131: 308-16.
19. Jurgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010; 105: 1811-9.
20. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
21. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
22. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18.
23. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009; 44: 774-81.
24. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Antiinfliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010; 69: 817-21.
25. Aybay C, Ozel S. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int 2006; 26: 473-80.
26. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010; 38: 82-9.
27. Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 2010; 16: 1898-904.
28. Suzuki Y, Yamada A, Sono K. A new assay for monitoring functional serum infliximab level in Crohn's disease patients. Gut 2011; 60: A190.
29. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-8.
30. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
31. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24.
32. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54.
33. Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth M. Can measurements of antiinfliximab antibodies predict acute severe infusion reactions to infliximab? Gastroenterology 2011; 140: S774.
34. Gisbert JP, Gonzalez-Lama Y, Mate J. Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease. Gastroenterol Hepatol 2006; 29: 568-83.
35. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate for the prevention of antibodies to infliximab in patients with Crohn's disease. Gastroenterology 2010; 138: S167-S8.
36. Van Moerkercke W, Ackaert C, Compernolle G, et al. High infliximab trough levels are associated with mucosal healing in Crohn's disease. Gastroenterology 2010; 5: S60.
37. Dastrich P, Kozeluhova J, Bortlik M, Bouzkova E, Jaresova M, Spicak J. Infliximab but not adalimumab serum trough level is a useful predictor of deep remission in patients with Crohn's disease. Gut 2011; 60: A186.
38. Li J, Chiu Y, Robinson A, Lomax K, Pollack PF, Paulson S. Evaluation of potential correlations between serum adalimumab concentration and remission in patients with Crohn's disease in CLASSIC I and II. J Crohns Colitis 2010; 4: S73.
39. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
40. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
41. van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and antiadalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010; 69: 624-5.
42. Vermeire S, Gabriels F, Ballet V, et al. The effect of dose escalation on through levels in patients who lost rresponse to infliximab. Gut 2010; 59: A81.
43. Lamblin C, Aubourg A, Ternant D, Picon L, Lecomte T, Paintaud G. Concentration-effect relationship of infliximab in Crohn's disease: results of a cohort study. J Crohns Colitis 2012; 6: S142.
44. Arias M, Vande Casteele N, Drobne D, et al. Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis. J Crohns Colitis 2012; 6: S5.
45. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease: a single cohort study. J Crohns Colitis 2012; 6: S153.
46. Afif W, Loftus EV Jr., Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
47. Vande Casteele N, Compernolle G, Ballet V, et al. Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled trough level adapted infliximab treatment (TAXIT) trial. J Crohns Colitis 2012; 6: S6.
48. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610.
49. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25.
50. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
51. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-83.
52. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a costeffectiveness analysis. Aliment Pharmacol Ther 2007; 26: 1509-20.
53. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
54. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8.
55. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
56. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
57. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122-6.
58. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBDsubgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-26.
59. Ferrante M, Ballet V, Geskens V, et al. Infliximab for severe iv steroidrefractory ulcerative colitis: can infliximab trough levels guide our management? Gastroenterology 2011; 140: S275-S6.